NASDAQ:HRTX

Heron Therapeutics Stock News

etoro logo Buy HRTX
*Your capital is at risk
$0.496
-0.0012 (-0.241%)
At Close: Jul 31, 2026
SAN DIEGO, May 25, 2021 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatm
Current & former penny stocks trading higher after surge of interest in biotech industry. The post Trading Penny Stocks?
Heron Therapeutics: Zynrelef (Finally) Approved But With A Narrow Label
Shares of Heron Therapeutics Inc (NASDAQ: HRTX) are higher after a long wait to get regulatory approval for its non-opioid pain drug. What Happened: San Diego, California-based Heron, a commercial-
The stock price of Heron Therapeutics Inc (NASDAQ: HRTX) increased by over 15% pre-market. This is why it happened.
SAN DIEGO, May 13, 2021 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatm

Why Heron Therapeutics Stock Jumped Today

03:33pm, Monday, 10'th May 2021
Investors liked the company's Q1 update.
Heron Therapeutics (HRTX) delivered earnings and revenue surprises of -1.75% and -25.90%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
SAN DIEGO, May 10, 2021 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatm

Want to Make Money in Biotech? Do This First

06:17am, Friday, 07'th May 2021
Keeping track of upcoming events is important.
Heron Therapeutics (HRTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Investors need to pay close attention to Heron Therapeutics (HRTX) stock based on the movements in the options market lately.
Heron Therapeutics (HRTX) delivered earnings and revenue surprises of 0.00% and 12.11%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Heron Therapeutics (HRTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
We look at Heron Therapeutics for the first time since it received a CRL from the FDA late last Spring. The shares are up approximately one-third since we recommended to buy in that dip as the company
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE